New antibody shows promise against Post-Transplant virus threat
NCT ID NCT07261215
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a new drug called zuberitamab as a first-line treatment for EBV infection in 20 adults who have had a stem cell transplant. EBV can cause a serious complication after transplant, and current treatments don't work for everyone. Zuberitamab is designed to be more effective at clearing the virus and preventing that complication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zuberitamab
What this could lead to
If it works, zuberitamab could offer a more effective first-line option to control EBV after transplant, potentially reducing the risk of a life-threatening complication.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply broadly. The drug may not work better than existing treatments, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HSCT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.